Luisa Theresa Balz

Ms. Luisa Theresa Balz

Neurology, University Hospital Ulm, Ulm, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
SGSimon J. Guillot
Simon J. Guillot
CLChristina Lang
Christina Lang
MSMarie Simonot
Marie Simonot
DBDaniel Beckett
Daniel Beckett
DLDorothée E. Lulé
Dorothée E. Lulé
MBMatei Bolborea
Matei Bolborea
Sleep alterations have been described in several neurodegenerative diseases yet are currently poorly characterized in amyotrophic lateral sclerosis (ALS). This study investigates sleep macroarchitecture and related hypothalamic signaling disruptions in ALS. Using polysomnography, we found that both patients with ALS as well as asymptomatic C9ORF72 and SOD1 mutation carriers exhibited increased wakefulness and reduced non–rapid eye movement sleep. Increased wakefulness correlated with diminished cognitive performance in both clinical cohorts. Similar changes in sleep macroarchitecture were observed in three ALS mouse models ( Sod1 G86R , Fus Δ NLS/+ , and TDP43 Q331K ). A single oral administration of a dual-orexin receptor antagonist or intracerebroventricular delivery of melanin-concentrating hormone (MCH) through an osmotic pump over 15 days partially normalized sleep patterns in mouse models. MCH treatment did not extend the survival of Sod1 G86R mice but did decrease the loss of lumbar motor neurons. These findings suggest MCH and orexin signaling as potential targets to treat sleep alterations that arise in early stages of the disease.

14 May 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
DTDaniela Taranu
Daniela Taranu
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
JHJill Holbrook
Jill Holbrook
VTVisal Tumani
Visal Tumani
HSHerbert Schreiber
Herbert Schreiber
IUIngo Uttner
Ingo Uttner
Background: Multiple sclerosis (MS) subtypes—relapsing–remitting (RRMS), secondary-progressive (SPMS), and primary-progressive (PPMS) – have been associated with distinct cognitive impairment profiles, with progressive subtypes, in contrast to RRMS, showing additional deficits in more widespread domains. Research has largely focused on RRMS, leaving SPMS and PPMS underexplored due to their lower prevalence and limited therapeutic targeting. Data on the interplay between cognitive impairment, mood, and fatigue over time are also scarce. This study examined cognition, fatigue, and psychopathology over a period of one year to identify subtype-specific impairments and progression trajectories. Methods: Sixty-six MS patients (22 each with RRMS, SPMS, and PPMS) and 22 healthy controls (HC) were assessed using neuropsychological tests for attention, memory, processing speed, working memory, fluency and visuospatial functions. Patient-reported outcomes for depression, anxiety, and fatigue were also collected. Analyses included correlations, within-group comparisons (paired t-tests), and between-group comparisons (ANOVAs/ANCOVAs). Results: Progressive MS subtypes exhibited more severe cognitive impairments, fatigue, and mood disturbances than RRMS. Over one year, treated RRMS patients improved in various cognitive domains, while PPMS patients showed gains only in visuospatial abilities. On the other hand, SPMS patients exhibited no significant changes, suggesting more pronounced cognitive deficits. Conclusions: Cognitive impairments differed significantly across MS subtypes. While RRMS patients improved over one year and PPMS patients showed selective gains in one domain, SPMS showed no significant changes, indicating reduced cognitive reserve. These between-group differences suggest different cognitive trajectories. The findings underscore the need for tailored, holistic interventions for different MS subtypes.

6 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CLChristina Lang
Christina Lang
SGSimon J. Guillot
Simon J. Guillot
DLDorothée E. Lulé
Dorothée E. Lulé
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
AKAntje Knehr
Antje Knehr
LDLuc Dupuis
Luc Dupuis
BACKGROUND: Amyotrophic lateral sclerosis (ALS), the major adult-onset motor neuron disease, is preceded by an early period unrelated to motor symptoms, including altered sleep, with increased wakefulness and decreased deep nonrapid eye movement (NREM). Whether these alterations in sleep macroarchitecture are associated with — or even precede — abnormalities in sleep-related EEG features remains unknown. METHODS: Here, we characterize sleep microarchitecture using polysomnography for patients with ALS ( n = 33) and controls ( n = 32) as well as for asymptomatic carriers of superoxide dismutase 1 ( SOD1 ) or C9ORF72 mutations ( n = 57) and noncarrier controls ( n = 30). Patients and controls with factors that could confound sleep structure, including respiratory insufficiency, were prospectively excluded. The results were complemented in 3 ALS mouse models ( Sod1 G86R , Fus ΔNLS/+ , and TDP-43 Q331K ). RESULTS: We observed a brain-wide reduction in the density of sleep spindles, slow oscillations, and K-complexes in patients with early-stage ALS and in presymptomatic gene carriers. These defects in sleep spindles and slow oscillations correlated with cognitive performance in both cohorts, particularly with scores on memory, verbal fluency, and language function. Alterations in sleep microarchitecture were replicated in 3 mouse models, and decreases in sleep spindles were rescued following intracerebroventricular supplementation of melanin-concentrating hormone (MCH) or by oral administration of a dual orexin receptor antagonist. CONCLUSION: Sleep microarchitecture was associated with cognitive deficits and causally linked to aberrant MCH and orexin signaling in ALS. FUNDING: Agence Nationale de la Recherche (ANR); Fondation Thierry Latran; Association Francaise de Recherche sur la sclérose latérale amyotrophique; Association Française contre les myopathies; TargetALS; and Joint Program on Neurodegenerative Diseases Research (JPND).

18 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
DEDeborah Katharina Erhart
Deborah Katharina Erhart
IUIngo Uttner
Ingo Uttner
DLDorothée E. Lulé
Dorothée E. Lulé
Hayrettin TumaniHayrettin Tumani
Hayrettin Tumani
Approximately 7% of adults develop Post-COVID-19 syndrome (PCS). Cognitive impairment is common, but its profile in PCS is not well defined and requires clearer differentiation from general (post-)illness effects. The aim of this study was to identify distinct cognitive profiles in PCS and to characterize them with respect to broader psychological factors such as fatigue, depression, anxiety, and personality. To this end, we assessed cognition, fatigue, depression, anxiety, and personality traits in PCS patients, convalescents (CV), healthy controls (HC), and post-viral syndrome patients (PV) of different etiology. Cognitive performance was assessed with an extensive protocol covering multiple cognitive domains, including verbal and nonverbal short-term memory, verbal and nonverbal working memory, verbal and nonverbal episodic memory, visuoconstruction, attentional functions, and executive functions, alongside patient-reported measures of fatigue, depression, anxiety, and personality, as well as self-reported information on lifetime psychiatric diagnoses. Group comparisons and discriminant analysis ( p = .065) identified the tests that best differentiate the groups, while exploratory cluster analysis allowed for data-driven group assignment. In this study, N = 54 PCS, N = 42 HC, N = 25 CV, and N = 12 PV were included. Patients with PCS show low mean scores and cluster into two subgroups: 7.5% with severe objective cognitive impairments (PCS SCI ) and 92.5% with cognitive performance comparable to CV, HC, and PV (Mixed (non-SCI) ). The PCS SCI subgroup showed pronounced objective impairments, particularly in attentional, memory, and executive domains. Across the entire PCS sample, objective cognitive impairments were not predicted by fatigue severity or affective state (depression or anxiety), although lifetime psychiatric disorders and cognitive fatigue were significantly more prevalent in PCS SCI . Among patients with PCS, a distinct subgroup of individuals presents with severe cognitive deficits, significant cognitive fatigue, and an increased lifetime vulnerability for psychiatric disorders, highlighting the need for targeted diagnostic assessments and personalized (psycho-)therapeutic interventions.

4 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
IUIngo Uttner
Ingo Uttner
DTDaniela Taranu
Daniela Taranu
DEDeborah Katharina Erhart
Deborah Katharina Erhart
TFTanja Fangerau
Tanja Fangerau
Hayrettin TumaniHayrettin Tumani
Hayrettin Tumani
Background/Objectives: Cognitive impairment is one of the most common and debilitating clinical features of Multiple Sclerosis (MS). Neuropsychological assessment, however, is time-consuming and requires personal resources, so, due to limited resources in daily clinical practice, information on cognitive profiles is often lacking, despite its high prognostic relevance. Time-saving and effective tools are required to bridge this gap. This study evaluates the sensitivity and specificity of a revised version of TRACK-MS (TRACK-MS-R), a recently published screening tool to identify cognitive impairment in MS in a fast and reliable way, offering a balance between efficiency and diagnostic yield for the individual patient. Methods: In this prospective cross-sectional study, 102 MS patients and 94 age-, sex-, and education-matched healthy controls (HC) completed an extensive neuropsychological assessment, including TRACK-MS-R, to test for cognitive processing speed (Symbol Digit Modalities Test, SDMT) and verbal fluency (Regensburger Word Fluency Test, RWT). Sensitivity of TRACK-MS-R was assessed by using the BICAMS-M battery as a reference, and specificity was determined by comparing MS patients to HC. Results: TRACK-MS-R demonstrated high sensitivity (97.44%) when compared to the gold standard as represented by BICAMS-M for early and accurately detecting cognitive impairment in MS patients. Additionally, as a potential cognitive marker, TRACK-MS-R showed a specificity of 82.98% in distinguishing MS patients from healthy controls. Conclusions: TRACK-MS-R proves to be a highly sensitive and time-efficient screening tool for detecting cognitive impairment in patients with MS, while demonstrating good specificity compared to HC. Whereas high sensitivity is a prerequisite for a valid screening tool, its relatively modest specificity compared to BICAMS-M (62.9%) calls for caution in interpreting standalone results but instead indicates more extensive neuropsychological testing. Its briefness and diagnostic accuracy support its implementation in routine clinical practice, particularly in time-constrained settings.

19 August 2025 in Life
Verified
Journal Article
Open access
PDF file
DEDeborah Katharina Erhart
Deborah Katharina Erhart
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
Hayrettin TumaniHayrettin Tumani
Hayrettin Tumani
Encephalitis is a potentially life-threatening condition with long-term neurological sequelae. However, data on early clinical, demographic, and diagnostic predictors of functional outcomes remain limited. We performed a retrospective monocentric study including 98 patients diagnosed with infectious encephalitis of various etiologies treated in the University Hospital Ulm between January 2014 and December 2024. Ordinal logistic regression models were applied to evaluate associations between admission characteristics and functional outcome at discharge, as measured by the modified Rankin Scale. Three multivariate models incorporating clinical, demographic, and MRI/EEG variables explained up to 53% of the variance in mRS at discharge (p < 0.001), outperforming models based solely on CSF parameters. Key predictors of poor functional outcome included ‘altered consciousness’ (OR 7.08, p < 0.001), higher ‘mRS at admission’ (OR 0.03–0.07 across categories, p < 0.001), ‘focal/generalized EEG slowing’ (OR 9.97, p < 0.001), ‘epileptiform EEG activity’ (OR 17.49, p < 0.001), ‘MRI: myelitis’ (OR 16.44, p = 0.004), and ‘intrathecal IgM synthesis’ (OR 8.93, p = 0.018). Conversely, ‘longer hospitalization’ (OR 0.13–0.17 for different intervals, p < 0.006) and ‘intrathecal IgG synthesis’ (OR 0.05, p = 0.03) were associated with more favorable outcomes. Despite the single-center and retrospective aspects of this study, our findings underscore a multifactorial pattern of outcome determinants in infectious encephalitis, highlighting the prognostic relevance of initial neurological status, electrophysiological abnormalities, and neuroimaging features.